Features | Partner Sites | Information | LinkXpress
Sign In
Advantech Europe
KOREA E & EX
Schiller

Noncompliant Coronary Balloon Helps Navigate Tortuous Anatomy

By HospiMedica International staff writers
Posted on 16 Jun 2014
Image: The NC Euphora noncompliant balloon dilatation catheter with tapered tip (Photo courtesy Medtronic).
Image: The NC Euphora noncompliant balloon dilatation catheter with tapered tip (Photo courtesy Medtronic).
A new noncompliant coronary balloon provides superior deliverability and controlled growth in challenging angioplasty procedures.

The NC Euphora Noncompliant Balloon Dilatation Catheter offers enhanced deliverability through tight lesions via proprietary PowerTrac technology, thus requiring less force application to provide tracking through tortuous anatomy. An optimized tapered tip design and low lesion entry profile improve flexibility and allow for reliable stent re-cross when traversing long, challenging lesions, so that the balloon does not catch on a strut when passing through a deployed stent.

The balloon is made of strong, durable, and flexible Low Inflation Growth, High Track (LIGHT) material that provides high pressure capability, enabling the NC Euphora to expand consistently within the stent area at a rated burst pressure—the maximum pressure that the balloon can be repeatedly inflated in a safe manner—of up to 20 atmospheres without bursting. Significantly low radial growth reduces unwanted vessel expansion and longitudinal growth beyond the stent length, minimizing damage to the surrounding healthy artery. The NC Euphora Noncompliant Balloon Dilatation Catheter is a product of Medtronic (Minneapolis, MN, USA).

“NC Euphora expands our interventional portfolio with another clinically-relevant tool that was developed with both interventionalists and cath lab teams' needs in mind,” said Jason Weidman, vice president and general manager of Medtronic's coronary business. “With the addition of a premium noncompliant balloon, our interventional customers have a complement to the other innovative Medtronic offerings throughout the entire procedure for their most difficult and challenging cases.”

“When using a noncompliant balloon, deliverability and re-cross are important characteristics, especially when faced with challenging coronary anatomy,” said consultant interventional cardiologist Robert Gerber, MD, PhD, of Eastbourne District General Hospital East Sussex Healthcare NHS Trust, and preclinical researcher for the NC Euphora balloon. “The NC Euphora balloon was designed to meet these demands and provide reliable performance with no tradeoffs in the moment that we need it most.”

Related Links:

Medtronic
Eastbourne District General Hospital East Sussex Healthcare NHS Trust



Channels

Critical Care

view channel

Transfusion Approach Reduces Death from Blood Loss

A new study shows that a blood transfusion with equal ratios of plasma, platelets, and red blood cells (RBCs) give patients a significantly better chance of survival. Researchers at the University of Maryland (College Park, USA), the University of Texas Health Science Center (Houston, USA), and other institutions conducted... Read more

Women's Health

view channel

Nitrous Oxide for Labor Makes US Comeback

Long used for its anxiolytic properties during labor in European countries and Canada, nitrous oxide (N2O) use is resurging in the United States. While in countries such as Norway, New Zealand, Sweden, Australia, and England, usage rates of inhalational N2O during parturition reach 70%, it has only recently become an... Read more

Health IT

view channel
Image: Remote Intelligent Telehealth Assistant (RITA) (Photo courtesy of PR Newswire).

Telehealth Robot Launched to Increase Productivity of Doctors in Clinics and Hospitals

A robot uses high-definition monitors, high-speed components, and wireless communications, and serves as a telehealth media center to give doctors more flexibility in treating and assisting patients remotely.... Read more

Business

view channel

Pfizer to Buy Hospira to Bolster Hospital Products

Pfizer (New York, NY, USA) has entered into a definitive merger agreement with Hospira (Lake Forest, IL, USA), in a move designed to significantly enhance their global established pharmaceutical (GEP) business, for a total enterprise value of approximately USD 17 billion. The strategic complementary combination will... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.